• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Monopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8/9/24 8:01:37 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNPR alert in real time by email
    mnpr20240807_8k.htm
    false 0001645469 0001645469 2024-08-09 2024-08-09
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): August 9, 2024
     
    MONOPAR THERAPEUTICS INC.
    (Exact name of registrant as specified in its charter)
     
    Delaware
     
    001-39070
     
    32-0463781
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (I.R.S. Employer
    Identification No.)
     
    1000 Skokie Blvd., Suite 350, Wilmette, IL
     
    60091
    (Address of principal executive offices)
     
    (Zip Code)
     
    (847) 388-0349
    Registrant’s telephone number, including area code
     
    N/A
    (Former name or former address, if changed since last report)
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which registered
    Common Stock, $0.001 par value
     
    MNPR
     
    The Nasdaq Stock Market LLC (Nasdaq Capital Market)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
     
    Emerging growth company ☒
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
     


     
    1

     
     
    Item 2.02 Results of Operations and Financial Condition
     
    On August 9, 2024, Monopar Therapeutics Inc. ("Monopar" or the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2024. A copy of this press release is attached hereto as Exhibit 99.1.
     
    The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
     
    Item 3.03 Material Modification to Rights of Security Holders.
     
    The information under Item 5.03 below is incorporated herein by reference.
     
    --12-31
    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
     
    On August 9, 2024, Monopar filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation to effect a 1 for 5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”).  The Certificate of Amendment provides that the Reverse Stock Split will become effective at 5:00 pm, Eastern Time, on Monday, August 12, 2024.  The Company’s common stock is expected to begin trading on a split adjusted basis at the open of trading on Tuesday, August 13, 2024 under the new CUSIP number 61023L207.  The Company’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “MNPR”.
     
    As described below under Item 5.07, the Reverse Stock Split was approved by the Company's stockholders at its Annual Meeting held on August 5, 2024, to be effected by the Company's Board of Directors within approved parameters. The Company’s Board of Directors approved the Reverse Stock Split at a ratio of 1-for-5 on August 5, 2024.
     
    Additional information on the Reverse Stock Split can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on July 22, 2024, which is available on the SEC’s website at www.sec.gov and on the Company’s website, www.monopartx.com.
     
    The Certificate of Amendment is filed as Exhibit 3.1 to this report and incorporated herein by reference.
     
    Item 5.07  Submission of Matters to a Vote of Security Holders.
     
    On August 5, 2024, Monopar held its Annual Meeting. A total of 17,601,827 shares of the Company’s common stock were entitled to vote as of July 12, 2024, the record date for the Annual Meeting, of which 9,321,746 shares were represented in person or by proxy at the Annual Meeting. At the Annual Meeting, the stockholders of the Company voted on the following proposals:
     
    (1) the election of six directors, to serve as directors until the Company’s next annual meeting of stockholders or until their respective successors are duly elected and qualified; 
     
    (2)  the ratification of the selection of BPM LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024;
     
    (3) the approval to amend the Company’s Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a split ratio of between 1-for-2 and 1-for-20 as determined by the Board of Directors in its sole discretion; and
     
    (4) the approval to amend the Company’s 2016 Stock Incentive Plan to increase the authorized shares of common stock available for awards thereunder, received the following number of votes
     
    2

     
     
    Proposal 1 – Election of Directors
     
    At the Annual Meeting, the voting results with respect to the proposal for the election of directors, included in the Company’s Proxy Statement on Schedule 14A for the Annual Meeting, were as follows:
     
    Director
    For
    Withheld
    Broker Non-Votes
    Christopher M. Starr, Ph.D.
    9,254,538
    67,208
    N/A
    Chandler D. Robinson, MD MBA MSc
    9,200,385
    121,361
    N/A
    Michael J. Brown, MSc
    9,250,364
    71,382
    N/A
    Raymond W. Anderson, MBA
    9,250,354
    71,392
    N/A
    Arthur J. Klausner, MBA
    9,246,695
    75,051
    N/A
    Kim R. Tsuchimoto
    9,085,495
    236,251
    N/A
     
    Accordingly, each of the foregoing persons was elected as a director at the Annual Meeting.
     
    Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm
     
    The voting results with respect to the proposal to ratify the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2024, were as follows:
     
    For
    Against
    Abstain
    Broker Non-Votes
    9,291,481
    17,496
    12,769
    N/A
     
    Accordingly, the Company’s stockholders ratified the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2024.
     
    Proposal 3 – Reverse Stock Split of Outstanding Shares 
     
    The voting results with respect to the proposal to amend the Company’s Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a split ratio of between 1-for-2 and 1-for-20 as determined by the Board of Directors in its sole discretion, prior to the one-year anniversary of the 2024 Annual Meeting, were as follows:
     
    For
    Against
    Abstain
    Broker Non-Votes
    9,207,565
    92,307
    21,874
    N/A
     
    Accordingly, the Company’s stockholders approved  the proposal to amend the Company’s Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of the Company’s common stock.
     
    Proposal 4 – Amendment to Stock Incentive Plan 
     
    The voting results with respect to the proposal to the approval to amend the Company’s 2016 Stock Incentive Plan to increase the authorized shares of common stock available for awards thereunder, were as follows:
     
    For
    Against
    Abstain
    Broker Non-Votes
    8,588,358
    720,552
    12,836
    N/A
     
    Accordingly, the Company’s stockholders approved the proposal to amend amend the Company’s 2016 Stock Incentive Plan.
     
    No other matters were submitted to a vote of stockholders at the Annual Meeting.
     
    3

     
     
    Item 7.01 Regulation FD Disclosure
     
    On August 9, 2024, the Company issued a press release announcing the Reverse Stock Split.  The press release is furnished as Exhibit 99.2 to this Report and incorporated herein by reference.
     
    Item 9.01 Financial Statements and Exhibits
     
    Exhibit No.  
     
    Description
    3.1   Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Monopar Therapeutics Inc.
    99.1
     
    Press Release Dated August 9, 2024
    99.2
     
    Press Release Dated August 9, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
    4

     
     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Monopar Therapeutics Inc.
     
           
    Date: August 9, 2024
    By:
    /s/ Karthik Radhakrishnan
     
     
    Name:
    Karthik Radhakrishnan
     
     
    Title:
    Chief Financial Officer
     
     
    5
    Get the next $MNPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNPR

    DatePrice TargetRatingAnalyst
    1/9/2026$115.00Overweight
    Morgan Stanley
    11/14/2025Strong Buy → Outperform
    Raymond James
    11/10/2025$115.00Outperform
    Leerink Partners
    10/13/2025$125.00Overweight
    Barclays
    9/9/2025$87.00Buy
    BTIG Research
    9/3/2025$77.00Outperform
    Oppenheimer
    9/3/2025$80.00Strong Buy
    Raymond James
    8/26/2025$70.00Buy
    H.C. Wainwright
    More analyst ratings

    $MNPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

    WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments. "2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease," said Chandler Robinson, MD, Chief Executive Officer of Monopar. "We also recently strengt

    3/27/26 1:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

    WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On September 14-15, 2025, the Company presented new data on the long-term neurological efficacy and safety of ALXN1840 (tiomolybdate choline) at the 150th American Neurological Association (ANA) Annual Meeting. Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the Univ

    11/13/25 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Monopar Therapeutics with a new price target

    Morgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00

    1/9/26 9:05:54 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics downgraded by Raymond James

    Raymond James downgraded Monopar Therapeutics from Strong Buy to Outperform

    11/14/25 9:54:47 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Monopar Therapeutics with a new price target

    Leerink Partners initiated coverage of Monopar Therapeutics with a rating of Outperform and set a new price target of $115.00

    11/10/25 8:46:42 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CCSO Rodriguez Susan

    4 - Monopar Therapeutics (0001645469) (Issuer)

    3/4/26 5:25:43 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Rodriguez Susan

    3 - Monopar Therapeutics (0001645469) (Issuer)

    3/4/26 5:25:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Robinson Chandler acquired 62,815 shares (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    1/30/26 2:31:04 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by Monopar Therapeutics Inc.

    10-K/A - Monopar Therapeutics (0001645469) (Filer)

    4/1/26 12:24:15 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Monopar Therapeutics (0001645469) (Filer)

    3/27/26 1:27:25 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Monopar Therapeutics Inc.

    10-K - Monopar Therapeutics (0001645469) (Filer)

    3/27/26 1:00:33 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    10/30/24 4:17:28 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    6/21/24 5:16:51 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Leadership Updates

    Live Leadership Updates

    View All

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

    Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease  NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community. Monopar, a clinical-stage biotechnology firm, is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers, and will utilize the labs and other resources in Helix 51 t

    1/23/25 1:10:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

    WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Octávio Costa, MD, as Chief Medical Officer. In this role, Dr. Costa will oversee global clinical development and regulatory affairs, and will provide strategic direction for Monopar's pipeline. Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs. He has extensive Phase 1 through 4 clini

    7/12/21 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    SC 13G - Monopar Therapeutics (0001645469) (Subject)

    11/6/24 3:13:14 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    SC 13G - Monopar Therapeutics (0001645469) (Subject)

    10/31/24 4:17:57 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care